TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02861677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Study: NCT01775930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
Study: NCT02969980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
Study: NCT01182727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salsalate
Description: Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
Study: NCT04047381

Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
Study: NCT01551303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Liquid metered-dose nasal spray, 30 IUs, administered once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched nasal spray placebo
Study: NCT02690636

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: daily fractions, five fractions per week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: daily fractions, five fractions per week.
Study: NCT00960349

Intervention type: DRUG
Group type: OTHER
Intervention: Cediranib
Description: Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.

Intervention type: DRUG
Group type: OTHER
Intervention: Cediranib
Description: Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.

Intervention type: DRUG
Group type: OTHER
Intervention: S-1
Description: Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Study: NCT02187575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX capsule
Study: NCT01902212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Study: NCT03959826

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management for activity completion
Description: Participants will earn chances to win prizes for completing specific job-related activities.
Study: NCT00756197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation Group 1
Description: Cryo Spray Ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation Group 2
Description: cryo spray ablation
Study: NCT01744002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder treatment and neck mobilization
Description: This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
Study: NCT03194711

Intervention type: DEVICE
Intervention: BVS implantation
Description: BVS implantation using conventional semicompliant or non-compliant balloon
Study: NCT01741506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin®)

Intervention type: DRUG
Group type: OTHER
Intervention: Dalteparin (Fragmin®)
Study: NCT03673501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral KIT/PDGFRA kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Oral receptor tyrosine kinase (RTK) inhibitor
Study: NCT03578146

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Rivaroxaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Rivaroxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00834730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N2O gas vs ketamine
Description: Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N2O gas vs ketamine
Description: Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
Study: NCT02283736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus SP1
Description: Tablet containing Lactobacillus rhamnosus SP1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Talc powder
Description: Tablet containing talc powder

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Scaling and root planning

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal treatment
Description: Scaling and root planning
Study: NCT03211143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: Test drug: CKD-381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: Test drug: CKD-381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Reference drug: Nexium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Reference drug: Nexium
Study: NCT01685957

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary treatment (STD)
Description: This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ned i vaegt (NIV)
Description: This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verdens bedste kur (VBK)
Description: This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals.
Study: NCT01433068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBTXR3
Description: One intratumor implantation by injection
Study: NCT04299048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: subcutaneous injection
Study: NCT04527211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Oral administration of ivermectin 200 mcg/kg every week for seven weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin
Description: Oral administration of ivermectin 200 mcg/kg every week for seven weeks
Study: NCT00005711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma self-management education
Description: Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish.
Study: NCT01432821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apomorphine (Experimental product)
Description: Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apomorphine (Experimental product)
Description: Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2
Study: NCT04446351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK6097608
Description: GSK6097608 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK6097608
Description: GSK6097608 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK6097608
Description: GSK6097608 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Cobolimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered as an IV infusion.
Study: NCT04254107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-TGT
Description: Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-TGT
Description: Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-TGT
Description: Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given by IV on Day 1 of each 21-day cycle
Study: NCT04185935

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01502137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
Study: NCT01312714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 3 tablets of 1000 IU daily for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets of 1000 IU daily for 26 weeks
Study: NCT02824536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous Infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous Infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous Infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous Infusion of 10-1074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous Infusion of 10-1074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous Infusion of 10-1074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion of Sterile Saline (NaCl 0.9%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion of Sterile Saline (NaCl 0.9%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion of Sterile Saline (NaCl 0.9%)
Study: NCT00900640

Intervention type: PROCEDURE
Intervention: ERCP as medically indicated by subjects referring physician
Description: Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
Study: NCT03619759

Intervention type: DRUG
Intervention: Sugammadex
Description: Sugammadex injection as a reverse agent of neuromuscular blocking
Study: NCT01625624

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Food Bar
Description: Control Food Bar containing carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Carbohydrate Food Bar
Description: Test Food Bar containing modified carbohydrate
Study: NCT02162992

Intervention type: OTHER
Intervention: No intervention
Description: Observational

Intervention type: OTHER
Intervention: No intervention
Description: Observational
Study: NCT02053428

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous image-guided gastrostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous image-guided gastrostomy
Study: NCT00245336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin
Description: 1000 U/mL applied topically in combination with absorbable gelatin sponge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bovine thrombin
Description: 1000 U/mL applied topically in combination with absorbable gelatin sponge
Study: NCT03877705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine ready tabs
Description: Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine ready tabs
Description: Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
Study: NCT01898520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
Study: NCT03558464

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention (integrated package)
Description: During whole study (pregnant women and offspring):~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~* LNS (Enov' Mum, 20g sachet daily)~* Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~* MNP (MixMe, 1g sachet every three days)~* ORS + zinc~* 1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements).
Study: NCT03900715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept
Study: NCT04233333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: method of fixation of the orogastric tube
Description: Methods of fixation of the orogastric tube will be randomized

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: method of fixation of the orogastric tube
Description: Methods of fixation of the orogastric tube will be randomized
Study: NCT01935193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lysine acetylsalicylate
Study: NCT01151878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucomannan
Description: 1.26 g per sachet; 2 sachets per day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: prepared in sachets (1.3g); 2 sachets per day for 4 weeks
Study: NCT01802892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret 100 mg
Description: Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret 400 mg
Description: Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
Study: NCT02602613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMEND Mitral Valve Repair System
Description: Annuloplasty ring applied in a transcatheter method